Sinolink Securities: "Spring excitement" may surpass expectations, focusing on the ultimate technology theme.

It is expected that the domestic 'easy mmf + loose fiscal policy' will usher in signs of marginal improvement from the macro, meso to micro levels.

Zhitong Finance17:36 ET

Minsheng Securities: The results of medical insurance negotiations are now available, key products successfully included in the medical insurance catalog.

With the support of policies such as health insurance, the level of new drug research and development in China is continuously improving, the industrial scale is constantly expanding, and the number of new drugs under development in the country has jumped to the second place globally, accelerating the transition to high-quality innovation.

Zhitong FinanceNov 29 00:35 ET

Minsheng Securities: Maintains a "recommendation" rating for the Coln Bio-B (06990). Lepu alshatuzumab monoclonal antibody approved for listing.

Mingsheng Securities estimates that the net income attributable to shareholders of Kelun Botai for 2024, 2025, and 2026 will be -0.138 billion yuan, -0.618 billion yuan, and -0.133 billion yuan, respectively.

Zhitong FinanceNov 28 04:14 ET

Brokerage Focus: BOCOM International initiates coverage on Coronado Bio (06990) with a "buy" rating, stating that it is expected to become an industry leader in the ADC wave.

Jingu Finance News | Pu silver international released research reports, pointing out that Antibody-drug conjugate (ADC) is a hot area in tumor drug development in recent years. According to Frost&Sullivan's forecasts, the global ADC market size is expected to grow rapidly from $7.9 billion in 2022 to reach $64.7 billion in 2030 (corresponding to a 30% CAGR), while china ADC market is expected to grow from 0.8 billion yuan in 2022 to 66.2 billion yuan in 2030 (corresponding to 73% CAGR). The bank further points out that china has become a global

Jingwu Financial NewsNov 27 02:55 ET

Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod Marketing Approval for Breast Cancer Drug; Share Up 5%

MT NewswiresNov 27 01:28 ET

Core product Sacituzumab Govitecan (sac-TMT) of Kelunpo Tai Biotechnology-B (06990.HK) based on the OptiTROP-Breast01 study for the treatment of second-line and above TNBC has been approved for market by the National Medical Products Administration.

Gelonghui November 27th | Collenbo Tai Biotechnology-B (06990.HK) announced that the company's first domestically produced targeted antibody-drug conjugate (ADC) Luconshatuzumab monokomal (sac-TMT, formerly known as SKB264/MK-2870) for unresectable local advanced or metastatic triple-negative breast cancer (TNBC) adult patients who have received at least two previous systemic treatments (at least one of which targets advanced or metastatic stages) of targeting the human trophoblastic cell surface antigen 2 (TROP2) has been approved by the National Medical Products Administration (NMPA) for marketing in China. This batch

Gelonghui FinanceNov 26 23:16 ET